Loading viewer...
earnings
Format: PDF earnings
Teva Pharmaceutical Industries reported fourth quarter and full year 2023 financial results, discussing its Pivot to Growth strategy focused on expanding innovative medicines and biosimilar portfolios while managing generic product dependencies. The presentation outlines operational challenges including supply chain disruptions, geopolitical impacts, and regulatory compliance matters.
earnings
37 Pages
earnings
25 Pages
Advanced Emissions Solutions